NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Demo Report

Report Issued 03/30/2020 12:26
Last Report Issued 02/22/2010 13:51

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 2395SP
Patient ID 2395SP
Chain 10000431
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 10000431

Received 02/22/2010 13:49

Sample ID 10000431-001
Matrix Serum or Plasma
Patient Name 2395SP
Patient ID 2395SP
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
2395SP Iloperidone, Serum/Plasma				
Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)				
Iloperidone	None Detected	ng/mL	0.25	
Synonym(s): Fanapt®; Fanapta®; Zomaril®				
Peak plasma levels of iloperidone are achieved 2 to 4 hours after ingestion. Steady-state concentrations are attained within 3 to 4 days of dosing. The mean plasma level for iloperidone ranges from 2.2 - 2.7 ng/mL following a single 3 mg dose. In one study that examined the pharmacokinetic and pharmacodynamic relationship in regard to iloperidone efficacy, maximal response in terms of therapeutic benefit was observed at plasma concentrations of 5 - 8 ng/mL. Genetic variations may substantially influence the rate of iloperidone metabolism.				

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.